عيادات السعودي المصري Saudi Egyptian Clinics

04/05/2026

Dr Mohamad Ahmad
Management of pulmonary hypertension
.......................................
Management of Pulmonary Hypertension depends heavily on the cause (group 1–5 classification) and severity, but most patients are treated using a combination of general measures, targeted medications, and sometimes procedures.
1. General & Supportive Management
These apply to most patients:
Oxygen therapy → if hypoxic
Diuretics → for fluid overload/right heart failure
Anticoagulation → especially in:
Chronic Thromboembolic Pulmonary Hypertension
Exercise rehabilitation (supervised)
Vaccinations (influenza, pneumococcal)
2. Treat the Underlying Cause
Pulmonary hypertension is classified into 5 groups:
Group 1: Pulmonary Arterial Hypertension (PAH)
Idiopathic, connective tissue disease, congenital heart disease
Group 2: Due to Left Heart Disease
Treat heart failure, valve disease
Group 3: Due to Lung Disease
COPD, interstitial lung disease → treat lung condition + oxygen
Group 4: Chronic Thromboembolic Disease
Chronic Thromboembolic Pulmonary Hypertension
Surgical cure possible (see below)
Group 5: Multifactorial/unclear causes
3. Targeted Drug Therapy (Mainly for Group 1 & Some Group 4)
These drugs act on pulmonary vessels:
A. Nitric Oxide Pathway
Sildenafil
Tadalafil
→ Vasodilation, improved exercise capacity
B. Endothelin Receptor Antagonists
Bosentan
Ambrisentan
→ Reduce vasoconstriction
C. Prostacyclin Pathway
Epoprostenol
Treprostinil
→ Strong vasodilators (advanced disease)
D. Soluble Guanylate Cyclase Stimulator
Riociguat
→ Especially useful in CTEPH
4. Interventional & Surgical Options
For CTEPH:
Pulmonary Endarterectomy (PEA) → potentially curative
Balloon Pulmonary Angioplasty (BPA) → if inoperable
For Advanced Disease:
Atrial septostomy (palliative)
Lung transplantation (end-stage cases)
5. Special Situations
Pregnancy
High risk, especially in severe disease
Avoid teratogenic drugs (e.g., bosentan, riociguat)
Use specialist care
6. Risk-Based Treatment Strategy
Treatment is stepwise and individualized:
Low risk → oral combination therapy
Intermediate → dual/triple therapy
High risk → IV prostacyclin + aggressive management
Key Takeaways
Always identify the cause first
Some forms (like Chronic Thromboembolic Pulmonary Hypertension) are potentially curable
Others require lifelong combination therapy
Early referral to a specialized pulmonary hypertension center improves survival
)

04/05/2026

Dr Mohamad Ahmad

Management of pulmonary hypertension

Management of Pulmonary Hypertension depends heavily on the cause (group 1–5 classification) and severity, but most patients are treated using a combination of general measures, targeted medications, and sometimes procedures.
1. General & Supportive Management
These apply to most patients:
Oxygen therapy → if hypoxic
Diuretics → for fluid overload/right heart failure
Anticoagulation → especially in:
Chronic Thromboembolic Pulmonary Hypertension
Exercise rehabilitation (supervised)
Vaccinations (influenza, pneumococcal)
2. Treat the Underlying Cause
Pulmonary hypertension is classified into 5 groups:
Group 1: Pulmonary Arterial Hypertension (PAH)
Idiopathic, connective tissue disease, congenital heart disease
Group 2: Due to Left Heart Disease
Treat heart failure, valve disease
Group 3: Due to Lung Disease
COPD, interstitial lung disease → treat lung condition + oxygen
Group 4: Chronic Thromboembolic Disease
Chronic Thromboembolic Pulmonary Hypertension
Surgical cure possible (see below)
Group 5: Multifactorial/unclear causes
3. Targeted Drug Therapy (Mainly for Group 1 & Some Group 4)
These drugs act on pulmonary vessels:
A. Nitric Oxide Pathway
Sildenafil
Tadalafil
→ Vasodilation, improved exercise capacity
B. Endothelin Receptor Antagonists
Bosentan
Ambrisentan
→ Reduce vasoconstriction
C. Prostacyclin Pathway
Epoprostenol
Treprostinil
→ Strong vasodilators (advanced disease)
D. Soluble Guanylate Cyclase Stimulator
Riociguat
→ Especially useful in CTEPH
4. Interventional & Surgical Options
For CTEPH:
Pulmonary Endarterectomy (PEA) → potentially curative
Balloon Pulmonary Angioplasty (BPA) → if inoperable
For Advanced Disease:
Atrial septostomy (palliative)
Lung transplantation (end-stage cases)
5. Special Situations
Pregnancy
High risk, especially in severe disease
Avoid teratogenic drugs (e.g., bosentan, riociguat)
Use specialist care
6. Risk-Based Treatment Strategy
Treatment is stepwise and individualized:
Low risk → oral combination therapy
Intermediate → dual/triple therapy
High risk → IV prostacyclin + aggressive management
Key Takeaways
Always identify the cause first
Some forms (like Chronic Thromboembolic Pulmonary Hypertension) are potentially curable
Others require lifelong combination therapy
Early referral to a specialized pulmonary hypertension center improves survival.

04/05/2026

04/05/2026

04/05/2026

Dr Mohamad Ahmad
Treatment of pulmonary embolism with pregnancy
..................................

Managing chronic pulmonary embolism (CPE) during pregnancy—especially when it has progressed to Chronic Thromboembolic Pulmonary Hypertension—is complex and requires specialist, high-risk care (cardiology + obstetrics + hematology). The goals are to protect both mother and fetus while preventing clot progression.
Core Principles of Treatment in Pregnancy
1. Anticoagulation (Essential)
Heparin-based therapy is the safest option in pregnancy:
Low Molecular Weight Heparin (e.g., enoxaparin) → first-line
Unfractionated Heparin → used near delivery (shorter action, reversible)
Avoid:
Warfarin → teratogenic (especially 1st trimester)
Direct oral anticoagulants (e.g., Rivaroxaban, Apixaban) → not recommended due to limited safety data
2. Management of Pulmonary Hypertension (if present)
Pregnancy with significant CTEPH is high risk due to strain on the heart.
Riociguat → contraindicated in pregnancy (teratogenic)
Safer alternatives may include:
Oxygen therapy
Careful fluid management
In severe cases, selected pulmonary hypertension drugs under specialist guidance
3. Surgical / Interventional Options
Pulmonary Endarterectomy (PEA):
Usually deferred until after delivery unless life-threatening
Balloon Pulmonary Angioplasty (BPA):
Rarely done during pregnancy; considered only in critical cases in expert centers
4. Delivery Planning
Managed in a tertiary care center
Planned delivery (often early term) with:
Switch from LMWH → UFH before labor (to reduce bleeding risk)
Mode of delivery:
Vaginal delivery often preferred if stable
Cesarean if high risk or unstable condition
5. Postpartum Care
High risk of clotting → continue anticoagulation
Safe options during breastfeeding:
Heparins
Warfarin (can be restarted after delivery)
Important Reality
Pregnancy in women with significant Chronic Thromboembolic Pulmonary Hypertension carries high maternal risk, including heart failure and death. In severe cases, some guidelines even advise avoiding pregnancy or considering early termination—this is a serious, individualized decision made with specialists.
When to Seek Urgent Care
Worsening shortness of breath
Chest pain
Fainting (syncope)
Leg swelling/pain

04/05/2026

Dr Mohamad Ahmad.

Treatment of chronic pulmonary embolism (CPE)—often part of a broader condition called Chronic Thromboembolic Pulmonary Hypertension—focuses on removing or controlling long-standing clots and improving blood flow in the lungs. Management depends on severity, location of clots, and overall health.
1. Lifelong Anticoagulation
The foundation of treatment is blood thinners to prevent new clots:
Warfarin
Rivaroxaban
Apixaban
These don’t remove existing clots but stop progression.
2. Surgical Treatment (Potentially Curative)
Pulmonary Endarterectomy (PEA)
The gold standard for eligible patients
Surgical removal of organized clots from pulmonary arteries
Can significantly improve or even normalize lung pressures
Best for patients with proximal, operable disease.
3. Interventional Procedure
Balloon Pulmonary Angioplasty (BPA)
Minimally invasive catheter-based procedure
Used when surgery isn’t possible or as an adjunct
Improves blood flow by dilating narrowed arteries
4. Targeted Medical Therapy
For patients who are not surgical candidates or have persistent symptoms:
Riociguat
Specifically approved for CTEPH
Helps relax pulmonary arteries and improve circulation
Other pulmonary hypertension drugs may be used in selected cases.
5. Supportive Care
Oxygen therapy (if low oxygen levels)
Diuretics for fluid overload
Supervised exercise / pulmonary rehab
6. Inferior Vena Cava (IVC) Filter (Selected cases)
Prevents new clots from reaching lungs
Used when anticoagulation is contraindicated or ineffective
Key Point
Unlike acute pulmonary embolism, chronic disease can sometimes be cured with surgery, so early referral to a specialized center is crucial.....
01117715458

04/05/2026

DR. MOHAMAD AHMAD
..................
Chronic pulmonary embolism
generally refers to persistent organized thrombi in the pulmonary arteries following acute pulmonary embolism (PE), which can lead to chronic thromboembolic pulmonary disease (CTEPD) (with symptoms but without pulmonary hypertension at rest) or chronic thromboembolic pulmonary hypertension (CTEPH) (Group 4 pulmonary hypertension). CTEPH develops in roughly 3% of patients after acute PE and can also occur without a documented prior PE history.
It involves fibrotic obstruction of pulmonary arteries plus variable small-vessel vasculopathy, leading to increased pulmonary vascular resistance, right heart strain, and potential right heart failure. Diagnosis requires a high index of suspicion in patients with persistent dyspnea or signs of pulmonary hypertension after PE.
Key Principles of Treatment
Treatment is multidisciplinary (involving CTEPH experts, surgeons, interventionalists, and pulmonologists) and individualized based on operability, disease distribution (proximal vs. distal), hemodynamics, and comorbidities. Lifelong anticoagulation is foundational in nearly all cases to prevent new thrombi.
1. Anticoagulation (Lifelong in CTEPH/CTEPD)
Mainstay to prevent recurrent venous thromboembolism (VTE).
Direct oral anticoagulants (DOACs) (e.g., rivaroxaban, apixaban) are often preferred over vitamin K antagonists (VKAs like warfarin) in eligible patients due to convenience, efficacy, and lower bleeding risk. VKAs may be used in specific cases (e.g., antiphospholipid syndrome).
Duration: At least 3–6 months after acute PE, then extended/indefinite for unprovoked or persistent-risk cases, and lifelong for established CTEPH.
2. Surgical Treatment: Pulmonary Thromboendarterectomy (PTE/PEA)
Treatment of choice for operable CTEPH (typically proximal disease).
Potentially curative; involves removal of chronic thromboembolic material under cardiopulmonary bypass and deep hypothermic circulatory arrest at specialized centers.
Excellent outcomes at experienced centers (perioperative mortality ~2%, significant improvements in hemodynamics, symptoms, and survival).
Up to ~60–70% of patients may be operable; evaluation by an expert team is essential.b32008b96a3d
3. Balloon Pulmonary Angioplasty (BPA)
Percutaneous procedure using balloons to disrupt webs, stenoses, and obstructions (especially distal/inoperable disease).
Guideline-recommended (often Class I) for inoperable patients or residual pulmonary hypertension after PTE.
Performed in stages; improves hemodynamics, exercise capacity, and symptoms. Often combined with other therapies.deb1cc85d106
4. Medical Therapy for Pulmonary Hypertension
Riociguat (soluble guanylate cyclase stimulator) is specifically approved for inoperable CTEPH or persistent PH post-PTE.
Other pulmonary arterial hypertension (PAH) therapies (e.g., endothelin receptor antagonists, PDE-5 inhibitors, prostacyclins) may be used off-label or in combination, though evidence is stronger for riociguat in CTEPH.
Supportive care: Diuretics for right heart failure, oxygen if hypoxemic, supervised exercise/rehabilitation.ee44f0
5. Multimodal and Supportive Approaches
Many patients benefit from combined therapy (e.g., PTE + BPA + medical therapy).
Follow-up after acute PE: Screen for persistent symptoms/functional limitations for at least 1 year (e.g., via 6-minute walk test, echocardiography, V/Q scan) to detect CTEPD/CTEPH early.
Referral to a specialized CTEPH center for evaluation (right heart catheterization, pulmonary angiography, V/Q scintigraphy as key diagnostic tools).
Prognosis and Considerations
With modern treatment at expert centers, outcomes are excellent for operable cases, with major improvements in quality of life and survival. Inoperable cases also fare better with BPA and targeted medical therapy than in the past. Early diagnosis is critical, as delays worsen right heart function.
Important: This is general information based on current guidelines and reviews (e.g., CHEST, ESC/ERS, AHA). Management must be personalized by a qualified physician, ideally at a CTEPH reference center. Do not self-treat or adjust medications. Consult a healthcare professional for diagnosis and tailored recommendations.

04/05/2026

Dr Mohamad Ahmad
....................................................
The Pulmonary Embolism Severity Index (PESI) is a validated clinical prediction rule used to stratify risk and estimate 30-day mortality (and other adverse outcomes) in patients with acute pulmonary embolism (PE) after diagnosis.a88ae5
It helps guide decisions such as outpatient vs. inpatient management, especially by identifying low-risk patients suitable for early discharge or home treatment when social and clinical factors allow.cb5175
PESI Scoring Criteria
A points-based score is calculated from 11 variables:
Age: +1 point per year of age
Male s*x: +10 points
History of cancer (active or metastatic): +30 points
History of heart failure: +10 points
History of chronic lung disease: +10 points
Heart rate ≥ 110 bpm: +20 points
Systolic blood pressure < 100 mmHg: +30 points
Respiratory rate ≥ 30 breaths/min: +20 points
Temperature < 36°C (96.8°F): +20 points
Altered mental status (disorientation, lethargy, stupor, or coma): +60 points
Arterial oxygen saturation < 90% (on room air): +20 points
Total score = Sum of all applicable points.237550
Risk Classes and Approximate 30-Day Mortality
Class I (Very low risk): ≤65 points (~0–1.6% mortality)
Class II (Low risk): 66–85 points (~1.7–3.5%)
Class III (Intermediate risk): 86–105 points (~3.2–7.1%)
Class IV (High risk): 106–125 points (~4.0–11.4%)
Class V (Very high risk): >125 points (up to ~24.5% or higher)22c3a7
Low-risk patients (Classes I–II) often have low mortality/severe morbidity and may be candidates for outpatient management. Higher classes generally warrant inpatient care and closer monitoring.c4ea9b
Simplified PESI (sPESI)
A simpler 6-variable version exists for easier bedside use:
Age >80 years: +1
History of cancer: +1
History of chronic cardiopulmonary disease: +1
Heart rate ≥110 bpm: +1
Systolic BP

09/04/2026

The TIMI score for STEMI is used to estimate 30-day mortality risk in patients with ST Elevation Myocardial Infarction.
🫀 TIMI Risk Score for STEMI (0–14)
Each factor has a specific number of points:
📊 Clinical variables
Age
65–74 years → +2
≥75 years → +3
History of diabetes, hypertension, or angina → +1
Systolic BP 100 bpm → +2
Killip class II–IV (heart failure signs) → +2
Weight 4 hours → +1
📈 Risk Interpretation (Approximate)
Score
Mortality Risk
0–1
~1–2%
2–3
~2–5%
4–5
~5–10%
6–7
~10–20%
≥8
>20–30%
🚨 Why it matters
Helps predict early mortality
Guides urgency of reperfusion therapy (PCI or thrombolysis)
Identifies high-risk patients needing aggressive management
🧠 Easy way to remember
Think in 3 groups:
Age & history
Hemodynamic instability (BP, HR, Killip)
Presentation severity (anterior MI, delay)
🔑 Summary
Score range: 0–14
Higher score = higher risk of death
Used specifically in ST Elevation Myocardial Infarction patients....
Dr Mohamad Ahmad
Cardiology, catheterization and pacemaker
01117715458

09/04/2026

The TIMI score (Thrombolysis In Myocardial Infarction score) is a clinical tool used to estimate the risk of death and ischemic events in patients with Acute Coronary Syndrome, including Unstable Angina and Non-ST Elevation Myocardial Infarction.
🫀 TIMI Score for UA/NSTEMI (0–7)
Each of the following gives 1 point:
Age ≥ 65 years
≥3 risk factors for coronary artery disease
(e.g., diabetes, hypertension, smoking, family history)
Known coronary stenosis ≥50%
ST-segment deviation on ECG
≥2 anginal episodes in last 24 hours
Use of aspirin in last 7 days
Elevated cardiac biomarkers (e.g., troponin)
📊 Risk Interpretation
TIMI Score
Risk Level
Approx. Risk of events
0–1
Low
~5%
2–3
Intermediate
~8–13%
4–5
High
~20%
6–7
Very high
~40%
🚨 TIMI Score for STEMI (simplified)
Used in ST Elevation Myocardial Infarction, includes:
Age
Blood pressure
Heart rate
Killip class
Weight
Anterior MI or LBBB
Time to treatment
Diabetes/HTN/angina history
👉 Higher score = higher mortality risk
🧠 Why it matters
Helps decide early invasive vs conservative management
Predicts risk of death, MI, or recurrent ischemia
Guides urgency of treatment (e.g., angiography)
🔑 Simple memory trick (UA/NSTEMI)
Think:
“65 + risk factors + history + ECG + pain + aspirin + troponin”....
Dr Mohamad Ahmad
Cardiology, catheterization and pacemaker
01117715458

09/04/2026

Sgarbossa criteria are a set of ECG rules used to diagnose an acute Myocardial Infarction in patients who already have a Left Bundle Branch Block (or a paced rhythm), where the ECG is otherwise hard to interpret.
🫀 Why do we need it?
In LBBB, the ECG normally shows abnormal ST-T changes, so classic signs of MI (like ST elevation) become unreliable.
👉 Sgarbossa criteria help identify true ischemia despite this distortion.
📊 The 3 Sgarbossa Criteria
Each criterion has a score:
1️⃣ Concordant ST elevation (Score: 5)
ST elevation ≥1 mm
In leads where the QRS is positive (same direction)
✅ Most specific for MI
2️⃣ Concordant ST depression in V1–V3 (Score: 3)
ST depression ≥1 mm
In right precordial leads (V1–V3)
3️⃣ Discordant ST elevation (Score: 2)
ST elevation ≥5 mm
In leads where QRS is negative (opposite direction)
⚠️ Least specific
🧮 Interpretation
Score ≥3 → strongly suggests acute MI
The higher the score, the more likely a true infarction
🔬 Modified Sgarbossa (important update)
The third criterion was improved using a proportional rule:
👉 Replace:
ST elevation ≥5 mm
👉 With:
ST elevation ≥25% of the depth of the S wave
✔️ This makes it more accurate and sensitive
🧠 Simple summary
Used when ECG is hard to read (like LBBB)
Looks for abnormal ST changes that “break the rules” of LBBB
Score ≥3 → think acute MI......
Dr Mohamad Ahmad
Cardiology, catheterization and pacemaker
01117715458

09/04/2026

A hyperacute T wave is an early ECG sign of acute myocardial infarction, appearing before the classic ST-segment elevation.
🫀 What is a hyperacute T wave?
It is a tall, broad, and symmetric T wave seen on an ECG, indicating very early myocardial ischemia.
Tall (higher than normal)
Wide/bulky (not sharp like normal T waves)
Symmetrical (both sides look similar)
⚠️ Why does it happen?
When a coronary artery becomes suddenly blocked (as in Myocardial Infarction):
The affected heart muscle becomes ischemic
Potassium shifts occur in the cells
This alters repolarization → producing hyperacute T waves
⏱️ When do you see it?
Very early stage (minutes after occlusion)
Often transient (may disappear quickly)
Followed by:
ST elevation
Q waves (later)
📉 Where are they seen?
They appear in leads corresponding to the affected area:
Inferior MI → leads II, III, aVF
Anterior MI → V1–V4
🔍 Important distinction
Hyperacute T waves can be confused with those seen in Hyperkalemia, but:
Feature
Hyperacute T waves (MI)
Hyperkalemia
Shape
Broad, rounded
Narrow, peaked ("tent-like")
Distribution
Localized to affected leads
Diffuse (all leads)
🧠 Simple summary
Earliest ECG sign of MI
Tall, wide, symmetric T waves
Localized to affected region
Quickly progresses to ST elevation.....
Dr Mohamad Ahmad Cardiology, catheterization and pacemaker
01117715458